VEGFA and endometrial carcinoma: Antiangiogenic monotherapies, including targeting the VEGF pathway, resulted only in a modest normalization or failed completely (81, 82), and a promising targeting of ALK1 has recently not fulfilled the efficacy objective in phase II studies of patients with endometrial carcinoma (34) and metastatic squamous cell carcinoma (83).